Armistice Capital, LLC Cyclo Therapeutics, Inc. Transaction History

Armistice Capital, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.82 - $2.27 $268,140 - $742,290	-327,000 Reduced 35.16%	603,000 $506,000
Q4 2022 Feb 14, 2023	BUY	$0.95 - $2.13 $883,500 - $1.98 Million	930,000 New	930,000 $1.32 Million
Q4 2020 Feb 16, 2021	BUY	$3.85 - $16.0 $385,000 - $1.6 Million	100,000 New	100,000 $435,000

2.25M

Ticker CYTH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 8,439,440
Market Cap $5.32M
Description
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Armistice Capital, LLC with notifications on news.